Together, these results led to the general notion that aberrant activation of the ISG15 pathway may be conferring a motile phenotype to breast cancer cells by disrupting cell architecture and stabilizing proteins involved in breast cancer cell migration, invasion, and promoting breast tumorigenesis by stabilizing oncoproteins [79,157]. This evidence concerns the gene ISG15 and breast carcinoma.